| First Author | Marciniak E | Year | 2017 |
| Journal | J Exp Med | Volume | 214 |
| Issue | 8 | Pages | 2257-2269 |
| PubMed ID | 28652303 | Mgi Jnum | J:247314 |
| Mgi Id | MGI:5915141 | Doi | 10.1084/jem.20161731 |
| Citation | Marciniak E, et al. (2017) Tau deletion promotes brain insulin resistance. J Exp Med 214(8):2257-2269 |
| abstractText | The molecular pathways underlying tau pathology-induced synaptic/cognitive deficits and neurodegeneration are poorly understood. One prevalent hypothesis is that hyperphosphorylation, misfolding, and fibrillization of tau impair synaptic plasticity and cause degeneration. However, tau pathology may also result in the loss of specific physiological tau functions, which are largely unknown but could contribute to neuronal dysfunction. In the present study, we uncovered a novel function of tau in its ability to regulate brain insulin signaling. We found that tau deletion leads to an impaired hippocampal response to insulin, caused by altered IRS-1 and PTEN (phosphatase and tensin homologue on chromosome 10) activities. Our data also demonstrate that tau knockout mice exhibit an impaired hypothalamic anorexigenic effect of insulin that is associated with energy metabolism alterations. Consistently, we found that tau haplotypes are associated with glycemic traits in humans. The present data have far-reaching clinical implications and raise the hypothesis that pathophysiological tau loss-of-function favors brain insulin resistance, which is instrumental for cognitive and metabolic impairments in Alzheimer's disease patients. |
